Endocrinology

Your daily dose of the clinical news you may have missed.

Findings from new study suggest that promoting healthy coping strategies for stress during early life can reduce cardiometabolic risk, report researchers.

Your daily dose of the clinical news you may have missed.

While the FDA's preliminary evaluation has not surfaced evidence of a link, the agency says it "cannot definitively rule out that a small risk may exist," and so will continue research.

Semaglutide was associated with a lower risk of first-time and recurrent suicidal ideations in patients with obesity or overweight or T2D, according to new study.

The novel nonhormonal compound significantly reduced vasomotor symptoms and sleep disturbance while improving quality of life, according to findings.

Individuals with "lean NAFLD" may be at similar risk of NASH, cirrhosis, nonliver cancer, and death as as those with NAFLD and overweight or obesity, authors say.

In an open letter to the public, Lilly decries use of tirzepatide products Mounjaro and Zepbound for nonmedical purposes and warns of counterfeit formulations.

Your daily dose of the clinical news you may have missed.

The American Board of Obesity Medicine says annual first-time certificates now exceed those for cardiology, pulmonology, and medical oncology.

Study participants randomized to placebo for 1 year after 36 weeks on tirzepatide had mean weight regain of 14% vs augmented loss among those who continued on the medication.

While incretin-based antiobesity medications are the optimal treatment for some, there are other less costly approaches that can support weight loss success, this author says.

The dual GIP/GLP-1 mimetic is available by prescription for adults with obesity or overweight with comorbidities and Lilly is offering a savings card program.

Crinecerfont was granted FDA breakthrough therapy designation for the treatment of congenital adrenal hyperplasia.

Your daily dose of the clinical news you may have missed.

The 5 leading advocacy groups said the safety of people with obesity is at risk and called on the FDA to change clinical trial inclusion requirements and expedite labeling changes.

Your daily dose of the clinical news you may have missed.

Review the ACC/AHA guidelines on prevention of ASCVD through lifestyle and risk factor assessment and management in our at-a-glance slide show.

Cardiovascular mortality has been increasing among middle-aged US adult since 2011; a new study looked at changes in CV risk factors by income level over the past 20 years.

Chiadi Ndumele, MD, PhD, MHS, offers 3 thoughts for primary care on incorporating CKM syndrome screening into daily clinical practice.

"Primary care physicians... really are like the quarterbacks" for initiating multidisciplinary care for CKM syndrome, says Dr Chiadi Ndumele.

Absolute risk assessment for CVD remains the corner-stone of clinical primary prevention efforts. The new AHA prediction models expand that foundation.

Your daily dose of the clinical news you may have missed.

Managing cardiovascular-kidney-metabolic syndrome on a population-wide basis requires that social determinants of health be treated like any other risk factor, according to Ndumele.

Dr Chiadi Ndumele explains the need for the more comprehensive and also nuanced qualitative approach to estimating long-term CVD risk.

Chiadi Ndumele, MD, PhD, MHS, of Johns Hopkins University, details features of the new 4-stage construct that guides CKM diagnosis and promotes early disease intervention.

The second GLP-1 mimetic-based drug approved for chronic weight management, tirzepatide may outperform semaglutide, the first.

NAFLD, a term coined in the mid-nineteenth century but never an accurate name for the diseases it now stands for, was ready to go, agreed international experts.

Your daily dose of the clinical news you may have missed.

Tirzepatide could help individuals who lose weight with lifestyle change to maintain and augment that loss, a well known challenge among persons with obesity.